
|Videos|May 21, 2020
A 49-Year-Old Man With Steroid-Refractory Chronic Graft Versus Host Disease
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Corey S. Cutler, MD, MPH, FRCPC, provides insight on the case of a 49-year-old man with chronic GVHD and reviews current and emerging treatment options for disease management.
Advertisement
Case: A 49-Year-Old Man With Steroid-Refractory Chronic Graft Versus Host Disease
Initial presentation
- A 49-year-old man complains of “color and texture” changes to his skin, nails and the inside of his mouth; he also complains of shoulder and elbow joint discomfort limiting his normal daily activity
- PMH: he underwent matched related allogenic transplant from his brother for treatment of AML
- PE: depigmentation and lichen planus-like features noted on his chin, nose, cheeks and forearms bilaterally, and in the oral mucosa (~40% BSA); longitudinal ridging of the fingernails; joint stiffness and decreased range of motion
Clinical workup
- Labs: plt 70 x 109/L, total bilirubin 7.6 mg/dl, AST 150 U/L, ALT 165 U/L, ALP 430 U/L
- Negative for HBV, HBV, CMV, EBV, HHV-6
- NIH Global Severity of cGvHD moderate cGvHD; P-ROM score 4
- ECOG 1
Treatment
- Tacrolimus + dexamethasone oral rinse
- No treatment response after 4 weeks
- He was started on ruxolitinib 5 mg PO BID which was tolerated well; increased to 10 mg PO BID on day 6
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































